总结1例川崎病休克综合征合并中型冠状动脉瘤及颅内出血患儿的护理体会。针对川崎病休克综合征病死率高,并发冠状动脉瘤易形成血栓导致心肌缺血、梗死甚至猝死,并发颅内出血早期无特异性临床表现等难点,护理要点：迅速纠正川崎病休克综合征;关注神经系统等症状,早期识别颅内出血征象并及时干预;精准应用抗凝药物,预防冠状动脉瘤可能导致的并发症;制订个体化家庭护理方案,促进积极随访。经过13 d的积极治疗与精心护理,患儿病情得到控制,转至心内科治疗后好转出院,随访6个月状态良好。
To summarize the nursing experience of a child with Kawasaki disease shock syndrome complicated with medium coronary aneurysm and intracranial hemorrhage. We should targeted at the nursing difficulties,including the high mortality of Kawasaki disease shock syndrome,complicated coronary aneurysm which was easy to form thrombus leading to myocardial ischemia,infarction and even sudden death,and no specific clinical manifestation in the early stage of intracranial hemorrhage. Nursing points：medical cooperation to quickly correct Kawasaki disease shock syndrome;continuous dynamic observation of the child with vital signs and nervous system abnormal changes,effective identification of signs of intracranial hemorrhage and timely intervention;precise application of anticoagulant drugs to prevent complications caused by coronary aneurysm;developing individualized home care plan to promote positive follow-up. After 13 days of active treatment and intensive care,the patient's condition was controlled,and transferred to the Department of Cardiology for consolidation treatment,then he was discharged and in good condition during six months follow-up.
[1] Fukazawa R,Kobayashi J,Ayusawa M,et al.JCS/JSCS 2020 gui-deline on diagnosis and management of cardiovascular sequelae in Kawasaki disease[J]. Circ J,2020,84(8):1348-1407.
[2] 刘力. 川崎病休克综合征的早期识别与处理[J]. 中国小儿急救医学,2020,27(5):346-348.
Liu L.Early identification and management of Kawasaki disease shock syndrome[J]. Chin Pediatr Emerg Med,2020,27(5):346-348.
[3] 徐南娇,胡蕾. 1例免疫检查点抑制剂相关重症心肌炎患者合并心源性休克的护理[J]. 中华护理杂志,2022,57(17):2141-2144.
Xu NJ,Hu L.Nursing care of a patient with immune checkpoint inhibitors related cardiogenic shock after acute fulminant myocarditis[J]. Chin J Nurs,2022,57(17):2141-2144.
[4] 江莹,黎万汇,陈莹莹,等. 经外周静脉输注血管活性药物风险管理范围的综述[J]. 中华护理杂志,2021,56(7):1105-1110.
Jiang Y,Li WH,Chen YY,et al.A scoping review on risk management of peripheral vasoactive medication[J]. Chin J Nurs,2021,56(7):1105-1110.
[5] Kohli R,Chaturvedi S.Epidemiology and clinical manifestations of immune thrombocytopenia[J]. Hamostaseologie,2019,39(3):238-249.
[6] 赵春娜,杜忠东,高灵灵. 川崎病儿童冠状动脉病变危险因素分析[J]. 中华实用儿科临床杂志,2016,31(9):659-661.
Zhao CN,Du ZD,Gao LL.Risk factor analysis of coronary artery lesions in children with Kawasaki disease[J]. Chin J Appl Clin Pediatr,2016,31(9):659-661.
[7] 程婷,罗顺清,龙春莉,等. 川崎病并发巨大冠状动脉瘤的护理[J]. 护理实践与研究,2016,13(6):30-32.
Cheng T,Luo SQ,Long CL,et al.The nursing of Kawasaki disease with the complication of giant coronary artery aneurysm[J]. Nurs Pract Res,2016,13(6):30-32.
[8] 中华医学会儿科学分会心血管学组,中华儿科杂志编辑委员会. 川崎病冠状动脉病变的临床处理建议(2020年修订版)[J]. 中华儿科杂志,2020,58(9):718-724.
The Subspecialty Group of Cardiology,the Society of Pediatrics, Chinese Medical Association,Editorial Board of Chinese Journal of Pediatrics. Recommendations for clinical management of Kawasaki disease with coronary artery lesions(2020 revision)[J]. Chin J Pediatr,2020,58(9):718-724.
